Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. malaria
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Malaria Articles & Analysis

66 news found

Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study

Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study

Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. Ongoing research and numerous products in development make this market dynamic for newcomers entering the field. “According to the latest BCC Research study, ...

ByBCC Research


ImmunAdd attends Vaccines Summit 2022 in Washington DC

ImmunAdd attends Vaccines Summit 2022 in Washington DC

ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a ...

ByImmunadd, Inc.


Lumen Bioscience Announces Publication in NPJ Vaccines of Preclinical Data Demonstrating Needle Free, Spirulina-produced Vaccination Offering Protection Against Malaria

Lumen Bioscience Announces Publication in NPJ Vaccines of Preclinical Data Demonstrating Needle Free, Spirulina-produced Vaccination Offering Protection Against Malaria

The published research details how this platform was used to express a malaria protein antigen that can be delivered intranasally and later boosted with a simple oral booster. Treated mice demonstrate protection against subsequent malaria challenge. The low cost and scalability of Lumen’s production platform, coupled with easy, needle-free administration, ...

ByLumen Bioscience, Inc.


Acuitas Therapeutics President & CEO Named as a Pacific Winner in the EY Entrepreneur of the Year Award Program

Acuitas Therapeutics President & CEO Named as a Pacific Winner in the EY Entrepreneur of the Year Award Program

The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, rabies, tuberculosis, malaria and other serious ...

ByAcuitas Therapeutics


Discovery of a Whole New Class of Antimalarial Drugs Which Target PfGARP and Kill Malaria Parasites

Discovery of a Whole New Class of Antimalarial Drugs Which Target PfGARP and Kill Malaria Parasites

Artemisinin-based drug therapy remains the mainstay of treatment, but the spread of parasites resistant to this family of compounds threatens recent progress achieved by antimalarial campaigns and underscores the urgent need to identify new anti-malarial drugs. Surprisingly, WHO malaria treatment protocols do not reserve novel classes of antimalarials specifically for the ...

ByOcean Biomedical


Aesther Healthcare Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination

Aesther Healthcare Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination

Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most. ...

ByOcean Biomedical


Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Preliminary Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Preliminary Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.

Chirinjeev Kathuria commented, “Our executive team and our scientists are excited to partner with Aesther Healthcare to advance our cancer, fibrosis, and malaria discoveries into their Phase 1 trials, which have the potential to save tens of thousands of lives, including people suffering from Glioblastoma Multiforme, one of the most devastating forms of cancer, and patients ...

ByOcean Biomedical


Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction with White Lion Capital

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction with White Lion Capital

The closing of the up to $75 million purchase agreement with White Lion Capital will help advance our cancer, fibrosis, and malaria discoveries into their Phase 1 trials, and has the potential to alleviate suffering and save thousands of lives” said Dr. ...

ByOcean Biomedical


Aesther Healthcare (AEHA) Announces $75M Share Purchase Agreement for Ocean Biomedical Deal

Aesther Healthcare (AEHA) Announces $75M Share Purchase Agreement for Ocean Biomedical Deal

Providence, Rhode Island-based Ocean Biomedical is developing treatments for malaria and different cancer types. Ocean has since announced that it has discovered biospecific antibodies to target specific brain and lung cancers. ...

ByOcean Biomedical


Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Ocean Biomedical is accelerating development of a uniquely powerful malaria vaccine and several malaria therapeutics that target newly discovered pathways. ...

ByOcean Biomedical


Manus Bio receives additional funding to fight malaria through biotechnology

Manus Bio receives additional funding to fight malaria through biotechnology

“Ready access to this life-saving drug is such an important tool in the global fight against malaria. The additional funding we have received will enable us to translate a robust technology built with our BioAssemblyLineTM cell factory engineering platform into a fully scaled process.” A key time to beat malaria… Malaria ...

ByManus Bio


Michael Artley Named Senior Director, Information Technology at Acuitas Therapeutics

Michael Artley Named Senior Director, Information Technology at Acuitas Therapeutics

The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, rabies, tuberculosis, malaria and other serious ...

ByAcuitas Therapeutics


Taiwan Vaccine Adjuvant Pioneer ImmunAdd to Attend 2022 BIO International Convention in San Diego

Taiwan Vaccine Adjuvant Pioneer ImmunAdd to Attend 2022 BIO International Convention in San Diego

ImmunAdd’s next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against COVID-19, influenza, and cancer. IA-05 is accessible via total chemical synthesis and does not rely on extracts from Quillaja Saponaria or any other tree. ImmunAdd is undertaking the development of IA-05 in collaboration with several biopharma ...

ByImmunadd, Inc.


Turning a Great Idea into a Successful Product: ASPIRE

Turning a Great Idea into a Successful Product: ASPIRE

For VisionQuest’s vice president and principal investigator Vinayak Joshi (PhD), the journey from idea to commercial product has led him halfway around the world. Dr. Joshi recently traveled to Malawi, Kenya, Nigeria, and Ghana as part of his efforts to commercialize ASPIRE, his device for the detection and diagnosis of malarial retinopathy. While in Africa, he met with leaders in ...

ByVisionQuest Biomedical Inc.


Hyperfine Partners With Madonna’s Charitable Organization, Raising Malawi, to Increase Access to High Quality Healthcare for Children

Hyperfine Partners With Madonna’s Charitable Organization, Raising Malawi, to Increase Access to High Quality Healthcare for Children

” Half of Malawians are under the age of 15 and malaria remains a leading cause of death among children under the age of 5. Through a research partnership with the Mercy James Centre, Michigan State University procured a Hyperfine Swoop® portable MRI systemTM to facilitate critical research on cerebral malaria—the most severe form of the ...

ByHyperfine


Kephera Diagnostics receives Phase II contract from the National Cancer Institute for a test for liver fluke, an exotic parasite linked to bile duct cancer

Kephera Diagnostics receives Phase II contract from the National Cancer Institute for a test for liver fluke, an exotic parasite linked to bile duct cancer

Kephera scientists will work with collaborators at the National Institute of Malaria, Parasitology and Entomology in Vietnam, the country’s leading institution for research on human pathogenic parasites, and the Hanoi University of Public Health. ...

ByKephera Diagnostics, LLC


Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential

Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential

Additionally, in 2020, the foundation awarded a $4.2 million grant to Exscientia to identify new innovative treatments for malaria and tuberculosis – two of the world’s leading infectious disease killers – as well as new medicines for non-hormonal contraception. ...

ByExscientia


Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet

Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet

In addition, participants vaccinated with R21/Matrix-M showed high titers of malaria-specific anti-NANP antibodies 28 days after the third vaccination, which were almost doubled with the higher adjuvant dose. ...

ByNovavax


Amivas (US), LLC Announces U.S. Launch of Artesunate for Injection for Initial Treatment of Severe Malaria

Amivas (US), LLC Announces U.S. Launch of Artesunate for Injection for Initial Treatment of Severe Malaria

Artesunate for Injection 110 mg, powder and solvent for solution is launching in the U.S. for initial treatment of severe malaria in adult and pediatric patients. From 2007 until today, the product was available in the U.S. only through an expanded access investigational new drug (IND) program managed by the Centers for Disease Control and Prevention (CDC). ...

ByAmivas (US), LLC


EPA Announces Proposed Updates to List of Pests of Significant Health Importance

EPA Announces Proposed Updates to List of Pests of Significant Health Importance

Draft PR Notice 2020-X describes the groups of pests and their potential impact on public health as follows: Arthropods: The listed arthropods may cause asthma or trigger allergies, contaminate food, irritate skin, cause direct injury, or carry diseases such as epidemic typhus, trench fever, epidemic relapsing fever, malaria, encephalitis (St. Louis, Eastern, Western, West ...

ByBergeson & Campbell, P.C.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT